Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
Janssen 在預治療患者中獲得多發性骨髓瘤治療的條件批准
- Janssen Biotech Inc, a Johnson & Johnson (NYSE:JNJ) unit, received European conditional approval for Tecvayli (teclistamab) as monotherapy for relapsed or refractory multiple myeloma.
- Teclistamab is a T-cell redirecting bispecific antibody targeting both B-cell maturation antigen and CD3 discovered by Janssen scientists using Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) OmniAb OmniRat antibody discovery technology.
- Ligand's previously announced spin-off of OmniAb and merger (Business Combination) with Avista Public Acquisition Corp. II (NASDAQ: AHPA), a publicly traded special purpose acquisition company.
- Under the terms of the licensing agreement, OmniAb is eligible to receive a $10 million milestone payment upon the first commercial sale of teclistamab in the U.K., Italy, Germany, France, or Spain.
- Under the terms of the separation and distribution agreement between Ligand and OmniAb, the milestone payments related to the first commercial sale of Tecvayli will remain with the OmniAb business regardless of the timing and achievement of the milestone and the timing of the merger closing.
- Price Action: LGND shares are trading 0.45% higher at $103.81 on the last check Thursday.
- 揚森生技股份有限公司，一個強生紐約證券交易所代碼：JNJ）單位獲得歐洲有條件批准，對 Tecvayli（特克里他單抗）作為復發或難治多發性骨髓瘤的單一療法。
- 替克利他單抗是一種 T 細胞重定向雙特異性抗體，靶向由揚森科學家發現的 B 細胞成熟抗原和 CD3配件制药公司(NASDAQ: LGND) 全能抗體發現技術.
- Ligto 先前宣布將 OmniAB 分拆，並與上市交易的特殊目的收購公司 Avista 公共收購公司 II（納斯達克：AHPA）合併（業務合併）。
- 根據許可協議的條款，OmniAB 有資格在英國，意大利，德國，法國或西班牙首次商業銷售 teclistamab 時獲得 1000 萬美元的里程碑付款。
- 根據 Liga 和 OmniAB 之間的分離和分配協議條款，與 Tecvayli 首次商業銷售相關的里程碑性付款將保持在 OmniAB 業務中，無論里程碑的時間和實現以及合併結束的時間如何。
- 價格行動：LGND 股票在上次檢查星期四上漲 0.45%，報 $103.81 美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。